Antifungal Treatment Guidelines for HIV Patients

Initial Treatment

For mild focal pneumonia or clinically mild coccidioidomycosis infection in HIV patients, the Centers for Disease Control and Prevention recommends fluconazole 400 mg daily or itraconazole 400 mg daily as first-line therapy 1, 2, 3
For diffuse pulmonary involvement or severe extrathoracic disseminated coccidioidomycosis, the Centers for Disease Control and Prevention recommends amphotericin B as the preferred initial therapy (0.7-1.0 mg/kg daily of deoxycholate formulation) 2, 3
For coccidioidal meningitis, the Centers for Disease Control and Prevention recommends fluconazole 400-800 mg daily as the preferred treatment 2, 3

The Centers for Disease Control and Prevention recommends lifelong suppressive therapy with fluconazole 400 mg daily or itraconazole 200 mg twice daily after initial treatment for coccidioidomycosis 1, 3
For patients with focal pneumonia who have responded to therapy and have CD4+ counts >250 cells/μL on antiretroviral therapy, the Centers for Disease Control and Prevention considers discontinuing secondary prophylaxis after 12 months 1

The Infectious Diseases Society of America recommends fluconazole as the preferred agent for both oropharyngeal and esophageal candidiasis 3, 4, 5
For fluconazole-refractory cases of candidiasis, the Infectious Diseases Society of America recommends itraconazole oral solution, posaconazole, or IV amphotericin B 6, 7

The Centers for Disease Control and Prevention recommends antifungal therapy for all HIV patients with clinical evidence of coccidioidomycosis and CD4+ count <250 cells/μL 8
The Centers for Disease Control and Prevention advises considering drug-drug interactions when prescribing antifungal treatment alongside antiretrovirals, as all azole antifungals have potential for complex interactions with antiretroviral medications 8, 3
The Centers for Disease Control and Prevention recommends avoiding azole antifungals during the first trimester of pregnancy due to teratogenicity risk, and using amphotericin B as the preferred agent for treatment during the first trimester 3, 8

The Centers for Disease Control and Prevention (CDC) recommends that HIV-infected patients with positive Coccidioides serology and CD4 count <250 cells/µL should receive primary antifungal prophylaxis with fluconazole 400 mg daily or itraconazole 200 mg twice daily 9, 10, 11, 12
Patients living in endemic areas with positive serology are at increased risk for active infection, and the risk increases when CD4 count falls below 250 cells/µL 9, 10, 11, 12
Focal pneumonia is most common in patients with CD4 counts >250 cells/µL, while disseminated disease occurs in more immunosuppressed patients 9, 11, 12

The CDC recommends that primary prophylaxis should be considered for HIV-infected patients with positive Coccidioides serology and CD4 count <250 cells/µL 9, 10, 11, 12
If CD4 count is <250 cells/µL, prophylaxis with fluconazole 400 mg daily or itraconazole 200 mg twice daily is recommended 9, 10, 11, 12
If CD4 count is >250 cells/µL, no prophylaxis is indicated, but yearly serologic testing is recommended 9, 10, 11

Prophylaxis should be continued until CD4 count rises to >250 cells/µL for at least 6 months on antiretroviral therapy 9, 10, 11
Prophylaxis should be restarted if CD4 count subsequently falls below 250 cells/µL 9, 10, 11
Complement fixation titers should be monitored to assess for rising titers that might indicate active infection 10

The recommendations are based on CDC/NIH/IDSA guidelines from 2009, which represent the most comprehensive guidance on this topic 9, 10, 11, 12
The evidence quality is rated as BIII (moderate strength recommendation) for initiating prophylaxis with positive serology and CD4 <250 cells/µL 9, 10, 11, 12